Evidence map›Paper›PMID 40320508›Full record

ArticleScientific reports2025

In vitro models of microglia: a comparative study.

Zoe Woolf, Taylor J Stevenson, Kevin Lee, Blake Highet, Jena Macapagal Foliaki, Ramona Ratiu, Justin Rustenhoven, Jason Correia, Patrick Schweder, Peter Heppner and 6 more

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zoe Woolf *Department of Pharmacology, The University of Auckland, Auckland, New Zealand.
Taylor J Stevenson *Department of Pharmacology, The University of Auckland, Auckland, New Zealand.
Kevin LeeCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Blake HighetCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Jena Macapagal FoliakiDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand.
Ramona RatiuDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand.
Justin RustenhovenDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand.
Jason CorreiaCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Patrick SchwederDepartment of Neurosurgery, Auckland City Hospital, Auckland, New Zealand.
Peter HeppnerDepartment of Neurosurgery, Auckland City Hospital, Auckland, New Zealand.
Maria WeinertDepartment of Brain Sciences, Imperial College London, Dementia Research Institute, London, UK.
Natacha CoppietersDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand.
Thomas ParkDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand.
Johanna MontgomeryCentre for Brain Research, The University of Auckland, Auckland, New Zealand.
Amy M SmithDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand. amy.smith@auckland.ac.nz.
Michael DragunowDepartment of Pharmacology, The University of Auckland, Auckland, New Zealand. m.dragunow@auckland.ac.nz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglia perform key homeostatic functions to protect the central nervous system (CNS). However, in many brain disorders their protective functions are abrogated, contributing to disease progression. Therefore, studies of microglial function are critical to developing treatments for brain disorders. Different in vitro microglia models have been established, including primary human and rodent cells, induced pluripotent stem cell (iPSC)-derived models, and immortalised cell lines. However, a direct comparative analysis of the phenotypic and functional characteristics of these models has not been undertaken. Accurate modelling of human microglia in vitro is critical for ensuring the translatability of results from the bench to the brain. Therefore, our study aimed to characterise and compare commonly utilised in vitro microglia models. We assessed four established microglia models: primary human microglia, human iPSC-derived microglia, the human microglial clone 3 (HMC3) cell line, and primary mouse microglia, with primary human brain pericytes acting as a negative control. Primary human microglia, iPSC-derived microglia, and mouse microglia stained positive for myeloid-cell markers (Iba1, CD45 and PU.1), while HMC3 cells only stained positive for mural-cell markers (PDGFRβ and NG2). Distinct secretomes were observed in all cell models in response to inflammatory treatment, with iPSC-derived microglia showing the most significant inflammatory secretions. Notably, nitric oxide was only secreted by mouse microglia. Although all cell types exhibited phagocytic capacity, primary human microglia and iPSC-derived microglia displayed significantly higher levels of phagocytosis. Overall, comparative analysis revealed notable differences between human microglia, iPSC-derived microglia, HMC3 cells and mouse microglia. Such differences should be considered when using these models to study human brain diseases. Experimental findings obtained from mouse models or cell lines should ultimately be cross validated to ensure the translatability of results to the human condition.

Indexed as

MicrogliaModels, BiologicalAnimalsBiomarkersCell LineCells, CulturedHumansInduced Pluripotent Stem CellsMiceBiomarkersComparative analysisHuman microglial clone 3 (HMC3)In vitro modelsiPSC-derived microgliaMicroglia

Identifiers

PMID40320508
PMCPMC12050316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.